BIO CELL Terapia Celular

What BIO CELL Terapia Celular does

BIO CELL Terapia Celular Ltda. is a Brasília-based veterinary biotechnology company that develops, produces, and distributes mesenchymal stem cell (MSC) therapies for dogs, cats, and horses. The company's core technology is sourced from a rigorously controlled donor cell bank; cells are processed in an ISO7 clean room and undergo sterility testing, induction-to-differentiation testing, molecular marker certification, and post-thaw viability testing. In April 2020, BIO CELL became the first laboratory in the world to obtain MAPA (Brazil's Ministry of Agriculture) registration for three stem cell products, and is authorized to treat more than 20 diseases across the three species. The company reports more than 15,000 animals treated cumulatively, with documented clinical outcomes including an 80% walking-recovery rate in dogs with distemper neurological sequelae (UnB study) and approximately 83% clinical improvement in severe corneal ulcers.

BIO CELL generates revenue through a B2B2C model mediated by a network of affiliated veterinarians (Médicos Veterinários Afiliados) who diagnose, indicate, and apply the therapy, and through a franchise-like licensing model — the Unidade Avançada BIO CELL (UABC) — that grants partner clinics the SOPs, lab materials, training, and ongoing technical support to process cells locally under the BIO CELL brand. Direct consumer touchpoints include a website and WhatsApp channel that funnel pet owners to the nearest affiliated vet or UABC. Pricing is quote-based and not publicly disclosed. Since 2025, Vetnil, a traditional Brazilian animal-health company, has held a 62% majority stake, strengthening BIO CELL's distribution and capital base while founder/CEO Patrícia Malard continues to lead operations.

Name

BIO CELL Terapia Celular

Legal name

BIO CELL Terapia Celular Ltda.

Website

https://biocell.com.br

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

1–10 employees

Short description

BIO CELL Terapia Celular is a Brasília-based veterinary biotech that develops MAPA-registered mesenchymal stem cell therapies for dogs, cats, and horses, distributing treatments via affiliated veterinarians and a UABC franchise network across Brazil.

Ownership category

akta.pro rank

Headquarters

HQ city

Not specified

HQ country

Brazil

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Stem Cell Therapy Treatments (Veterinary B2B2C): Revenue is generated through the sale of stem cell treatments mediated by affiliated veterinarians and Unidade Avançada (franchise) partners. Pet owners pay for the treatment through veterinary clinics that source cells from BIO CELL's donor bank. The UABC franchisees pay for the right to operate under the BIO CELL model and receive cells/manuals/training.
2. UABC (Advanced Unit) Franchise/License Model: Veterinary clinics and laboratories can open a 'Unidade Avançada BIO CELL', receiving SOPs, lab materials, training, and ongoing support. This is a franchise/license revenue stream that also enables broader geographic distribution.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

BIO CELL Terapia Celular produces and distributes mesenchymal stem cell (MSC) therapy products sourced from a controlled donor bank and processed in an ISO7 clean room for the treatment of more than 20 diseases in dogs, cats, and horses. The products are MAPA-registered and delivered to pet patients either at the company's Advanced Units or at affiliate veterinary clinics nationwide. The company also licenses its Unidade Avançada BIO CELL (UABC) operating model, providing SOPs, lab materials, and training to third-party veterinary clinics so they can process and administer BIO CELL cells locally under the brand.

Product overview

BIO CELL Terapia Celular offers a unified stem cell therapy platform built around mesenchymal stem cell products registered with MAPA for dogs, cats, and horses. The portfolio centers on the BIO CELL stem cell product combined with a decentralized service delivery model through Unidade Avançada BIO CELL (UABC) franchise units and an affiliated veterinarian network. The company operates as a biotech-first organization providing cell therapy products, laboratory processing services, and clinical support infrastructure rather than a traditional software or multi-module SaaS platform.

Differentiator

Problem solved

Functional benefit

Products and services

• BIO CELL Stem Cell Therapy MAPA-registered mesenchymal stem cell therapy product for dogs, cats, and horses, covering more than 20 disease indications including osteoarthrosis, renal disease, atopic dermatitis, corneal ulcers, distemper neurological sequelae, fractures, and tendinopathies. Cells are sourced from a controlled donor bank, processed in an ISO7 clean room, and applied intravenously or locally by affiliated veterinarians or at Unidade Avançada BIO CELL units.
• Unidade Avançada BIO CELL (UABC) Franchise/License Licensable operating model for veterinary clinics and laboratories that want to establish a local advanced unit for stem cell processing and treatment delivery under the BIO CELL brand. Licensees receive SOPs, lab setup materials, processing manuals, clinical training, and ongoing technical support to maintain BIO CELL quality standards.
• Veterinary Affiliate Program (Médicos Veterinários Afiliados)

Quantifiable outcome

• 80% of distemper-affected dogs regained ability to walk after stem cell treatment (UnB study)
• +3 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• MOFA GlobalmoderateTechnology or Integration · 1 January 2013The 2013 partnership with American company MOFA Global introduced advanced technology that validated the BIO CELL protocol efficiency and opened doors for multiple research projects in the stem cell field. MOFA Global's technology supported the development and refinement of BIO CELL's cell processing methods.

Scale indicators9 records

Recent moves9 records

Expansion highlights5 records

Others

• Vetnil: Brazilian animal health company that acquired 62% of BIO CELL in 2025. Comparable as BIO CELL's parent/strategic owner with veterinary distribution and pharmaceutical capabilities in Brazil.
• MOFA Global: US-based reproductive technology provider that partnered with BIO CELL in 2013. Comparable as a technology partner whose input underlies BIO CELL's cell processing methods.

Direct peers

• Gallant (BodeVet): US-based veterinary stem cell bank and therapy provider offering ready-to-use stem cell treatments for dogs. Direct comparable as an allogeneic donor-bank model for companion animal regenerative medicine.
• VetStem Biopharma: US-based pioneer in veterinary regenerative medicine, offering autologous stem cell therapy for dogs, cats, and horses. Direct comparable as a leading veterinary stem cell provider with a similar clinical and regulatory focus.
• Ardent Animal Health (formerly MediVet): Provides regenerative medicine and stem cell solutions for companion animals and horses through a network of veterinary clinics. Highly comparable in service model and target customer segment.
• EquiCord / VetCell Equine: Specializes in equine stem cell banking and regenerative therapies, including umbilical cord blood banking. Comparable as a horse-focused stem cell therapy provider.

Broad incumbents

• Regeneus: Australian regenerative medicine company with veterinary and human cell therapy platforms. Comparable for veterinary cell therapy technology and clinical pipeline.
• Zoetis: Global animal health leader with extensive veterinary pharmaceutical and biological product portfolio. Comparable as a broad incumbent that could expand into veterinary regenerative medicine.

Emerging players

• AniCell Biotech: Provides regenerative therapies and biologics for horses and companion animals using amniotic-derived materials. Comparable as an emerging veterinary regenerative medicine player.

Regional players

• VetCell (Australia): Veterinary stem cell therapy provider focused on equine and companion animals in Australia/Asia-Pacific. Comparable as a regional veterinary stem cell player with similar indications and clinical model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Customer concentration

• YouTubeyoutube.com/channel/UCHnoMPy_RhvfqQHsqcgICFQ
• Facebookfacebook.com/biocellterapiacelular
• Instagraminstagram.com/celulastroncobiocell
• LinkedInlinkedin.com/company/bio-cell-terapia-celular

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BIO CELL Terapia Celular